Creo Medical Group (LON:CREO) Earns House Stock Rating from Shore Capital Group

Creo Medical Group (LON:CREO)‘s stock had its “house stock” rating reissued by equities researchers at Shore Capital Group in a research note issued on Thursday,London Stock Exchange reports. They presently have a GBX 40 target price on the stock. Shore Capital Group’s target price would suggest a potential upside of 185.71% from the company’s previous close.

Creo Medical Group Trading Up 0.9%

Shares of LON:CREO opened at GBX 14 on Thursday. The company has a debt-to-equity ratio of 8.20, a quick ratio of 2.19 and a current ratio of 3.22. The stock’s 50-day moving average is GBX 13.67 and its 200-day moving average is GBX 13.27. The company has a market cap of £68.01 million, a P/E ratio of 14.00 and a beta of 1.62. Creo Medical Group has a 52-week low of GBX 9.52 and a 52-week high of GBX 18.50.

Creo Medical Group (LON:CREO) last posted its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.The business had revenue of GBX 600 million for the quarter. Equities research analysts predict that Creo Medical Group will post -10.0800005 earnings per share for the current year.

Insider Activity at Creo Medical Group

In other Creo Medical Group news, insider Craig Jonathan Gulliford purchased 6,250 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was bought at an average cost of GBX 14 per share, for a total transaction of £875. Also, insider Richard John Rees acquired 6,250 shares of Creo Medical Group stock in a transaction dated Wednesday, July 1st. The stock was acquired at an average cost of GBX 14 per share, with a total value of £875. Insiders own 6.92% of the company’s stock.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.